Venezuela Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Venezuela Pharmaceuticals and Healthcare Report Q3 2013 Jul 10th 2013, 00:00, by rnrmahesh BMI View: As we have previously highlighted, Venezuela’s currency devaluation has an immediate negative impact on multinationals’ local financial performance reported in repatriated currency terms. We believe that foreign drugmakers will suffer from increasing government intervention, which aims to address high inflation as a consequence of the devaluation. Headline Expenditure Projections ? Pharmaceuticals: VEB43.5bn (US$10.1bn) in 2012 to VEB53.4bn (US$8.8bn) in 2013; +22.8% in local currency terms and -13.6% in US dollar terms. Forecast remains unchanged from Q213. ? Healthcare: VEB86.7bn (US$20.2bn) in 2012 to VEB106.6bn (US$17.5bn) in 2013; +22.9% in local currency terms and -13.5% in US dollar terms. … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=106046. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/venezuela-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions